Ambrilia Biopharma Inc. Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

MONTREAL, QUEBEC--(MARKET WIRE)--Jun 14, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, held its Annual General and Special Meeting today, during which the data reported yesterday on its novel series of HIV integrase inhibitors and recent developments were highlighted. The meeting was chaired by the new Chairman of the Board, Mr. Frederic Porte, and a progress report was presented by Mrs. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer, followed by a scientific review presented by Dr. Bonabes de Rouge, Senior Executive Vice-President and Chief Scientific Officer.